Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients

  • Authors:
    • Zhi Wang
    • Chengxue Dang
    • Kun Zhu
    • Yong Zhang
    • Dongmin Chang
    • Peng Xia
    • Yongchun Song
    • Kang Li
  • View Affiliations

  • Published online on: June 24, 2015     https://doi.org/10.3892/mco.2015.584
  • Pages: 1088-1092
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The occurrence of chemotherapy-induced alterations in markers of haemostasis during chemotherapy has been reported previously. However, the change of the haemostasis markers in the cyclophosphamide, epirubicin and fluorouracil (CEF) regimen remains unclear. The aim of the present study was to identify the change of the haemostasis markers during systemic chemotherapy (600 mg/m2 cyclophosphamide, 80 mg/m2 epirubicin and 500 mg/m2 fluorouracil; four courses over 21 days) to investigate its influence on the haemostasis markers of breast cancer patients and to discuss the requirement of anticoagulation therapy. D‑dimer, activated partial thromboplastin time (APTT), prothrombin time (PT) and fibrinogen (FIB) values were obtained before chemotherapy and on days 1, 4, 7 and 21. The results show that PT, D‑dimer and FIB were not prolonged prior to chemotherapy compared to that under the control. APTT was prolonged until day 4. The levels of D‑dimer and APTT were significantly higher compared to those of the breast cancer patients before receiving chemotherapy and controls on days 1, 4, 7 and 21 after chemotherapy. Alteration of the haemostasis markers occurred in the breast cancer patients under the CEF chemotherapy regimen. As there is an increased risk of deep vein thrombosis and pool prognosis of cancer patients, anticoagulant therapy should be considered.
View Figures
View References

Related Articles

Journal Cover

September-2015
Volume 3 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Z, Dang C, Zhu K, Zhang Y, Chang D, Xia P, Song Y and Li K: Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients. Mol Clin Oncol 3: 1088-1092, 2015
APA
Wang, Z., Dang, C., Zhu, K., Zhang, Y., Chang, D., Xia, P. ... Li, K. (2015). Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients. Molecular and Clinical Oncology, 3, 1088-1092. https://doi.org/10.3892/mco.2015.584
MLA
Wang, Z., Dang, C., Zhu, K., Zhang, Y., Chang, D., Xia, P., Song, Y., Li, K."Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients". Molecular and Clinical Oncology 3.5 (2015): 1088-1092.
Chicago
Wang, Z., Dang, C., Zhu, K., Zhang, Y., Chang, D., Xia, P., Song, Y., Li, K."Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients". Molecular and Clinical Oncology 3, no. 5 (2015): 1088-1092. https://doi.org/10.3892/mco.2015.584